⚡️⚡️⚡️
With energy prices rising, switch to a cheaper plan
💡
Compare Prices Now
⚡️⚡️⚡️

How to buy BioNTech (BNTX) shares in Australia

Learn how to easily invest in BioNTech shares.

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

BioNTech's COVID-19 vaccine (co-developed with Pfizer) has made headlines with the announcement of its 90% efficacy rate. But this early data is subject to change and the vaccine must pass rigorous testing by the Therapeutic Goods Administration’s (TGA) before it's approved for use in Australia.

BioNTech SE is a German biotechnology company founded in 2008. BioNTech's COVID-19 vaccine (co-developed with Pfizer) propelled the company into the spotlight in 2020 with the announcement of its 90% efficacy rate. As one of the front runners in the development of a successful global vaccine, BioNTech's share price has since surged more than 600% by June 2021.

How to buy shares in BioNTech

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for BioNTech. Find the share by name or ticker symbol: BNTX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until BioNTech reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$134.04, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of BioNTech, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of BioNTech. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

BioNTech stock price (NASDAQ:BNTX)

Use our graph to track the performance of BNTX stocks over time.

BioNTech shares at a glance

Information last updated 2022-06-20.
52-week rangeUS$119.7341 - US$457.9346
50-day moving average US$153.4516
200-day moving average US$214.8342
Target priceUS$253.57
PE ratio 2.4236
Dividend yield US$0 (1.33%)
Earnings per share (TTM) US$51.635

Compare trading apps to buy BioNTech shares

1 - 8 of 8
Name Product Standard brokerage for US shares Currency conversion fee Markets
eToro (global stocks)
US$0
50 pips (US$0.50 for every AU$100 exchanged)
Global shares, US shares, ETFs
Zero brokerage share trading on US, Hong Kong and European stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
US$0
0.70%
ASX shares, US shares, UK shares, ETFs, and more
Exclusive: Finder customers who apply for a share trading account in June will be able to trade Aussie shares from $2.50 commission until the end of August. T&Cs apply.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Tiger Brokers
Exclusive
Tiger Brokers
US$1.99
N/A
ASX shares, Global shares, Options trading, US shares, ETFs
Exclusive to Finder: Sign up to Tiger through Finder and on completion of your first deposit of any amount or transfer of shares receive 4 extra free grab shares. T&Cs apply.
Get started with $0 brokerage on ASX and US stocks for the first 3 months upon completion of your first qualifying deposit. Also receive a free Apple share if you deposit $3,000 or more.
SelfWealth (Basic account)
US$9.5
0.60%
ASX shares, US shares
Trade ASX and US shares for a flat fee of $9.50, regardless of the trade size.
New customers receive free access to Community Insights with SelfWealth Premium for the first 90 days. Follow other investors and benchmark your portfolio performance.
CMC Markets Invest
US$0
0.60%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 35,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges. Plus, buy Aussie shares for $0 brokerage up to $1,000. (Limited to one buy order per stock per trading day).
Bendigo Invest Direct
$0
0.60%
ASX shares, Global shares, Options trading, mFunds, ETFs, Warrants
Gain access to 12 markets from one account with Bendigo.
Invest in Australian shares and access major international markets through a trusted local brand. Plus, fine tune your investment knowledge with Bendigo’s advanced research and analysis tools.
Saxo Capital Markets (Classic account)
US$4
1%
ASX shares, Global shares, ETFs
Access 22,000+ stocks on 50+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
Superhero share trading
US$0
50 pips (US$0.50 for every AU$100 exchanged)
ASX shares, US shares, ETFs
Sign up & fund your account with A$100 or more and receive US$10 of Tesla stocks on Superhero. T&Cs apply.
Enjoy $0 brokerage on US stocks and buying ETFs as well as a flat $5 fee to trade Australian shares.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy BioNTech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

BioNTech share growth calculator

US$

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

BioNTech price performance over time

Historical closes compared with the last close of $134.04

1 week (2022-06-17) 7.11%
1 month (2022-05-26) -15.25%
3 months (2022-03-24) -21.34%
6 months (2021-12-23) -47.50%
1 year (2021-06-25) -41.73%
2 years (2020-06-26) 115.74%

Is BioNTech under- or over-valued?

Valuing BioNTech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioNTech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

BioNTech's P/E ratio

BioNTech's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, BioNTech shares trade at around 2x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

BioNTech's PEG ratio

BioNTech's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.0449. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioNTech's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

BioNTech's EBITDA

BioNTech's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$17.8 billion (£14.5 billion).

The EBITDA is a measure of a BioNTech's overall financial performance and is widely used to measure a its profitability.

BioNTech financials

Revenue TTM US$23.3 billion
Operating margin TTM 75.98%
Gross profit TTM US$16.1 billion
Return on assets TTM 90.32%
Return on equity TTM 139.59%
Profit margin 55.2%
Book value 65.473
Market capitalisation US$30.4 billion

TTM: trailing 12 months

BioNTech share dividends

4%

Dividend payout ratio: 3.95% of net profits

Recently BioNTech has paid out, on average, around 3.95% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.33% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), BioNTech shareholders could enjoy a 1.33% return on their shares, in the form of dividend payments. In BioNTech's case, that would currently equate to about $0 per share.

While BioNTech's payout ratio might seem low, this can signify that BioNTech is investing more in its future growth.

BioNTech's most recent dividend payout was on 17 June 2022. The latest dividend was paid out to all shareholders who bought their shares by 2 June 2022 (the "ex-dividend date").

BioNTech share price volatility

Over the last 12 months, BioNTech's shares have ranged in value from as little as US$119.7341 up to US$457.9346. A popular way to gauge a stock's volatility is its "beta".

Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioNTech's is -0.2923. This would suggest that BioNTech's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, BioNTech has bucked the trend.

BioNTech overview

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site